Novogene Co., Ltd. (SHA:688315)

Market Cap	5.61B
Revenue (ttm)	2.14B
Net Income (ttm)	203.35M
Shares Out	405.06M
EPS (ttm)	0.49
PE Ratio	28.47
Forward PE	24.89
Dividend	0.05 (0.35%)
Ex-Dividend Date	May 31, 2024

Volume	3,607,197
Average Volume	5,352,494
Open	13.86
Previous Close	13.76
Day's Range	13.76 - 14.17
52-Week Range	9.03 - 21.22
Beta	0.82
RSI	42.74
Earnings Date	Apr 15, 2025

About Novogene

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcripto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 2,144
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688315

Financial Performance

In 2024, Novogene's revenue was 2.11 billion, an increase of 5.45% compared to the previous year's 2.00 billion. Earnings were 196.79 million, an increase of 10.52%.